WEKO3
アイテム
視神経脊髄炎と抗アクアポリン抗体(神経内科学教室岩田誠教授退任記念特別号)
http://hdl.handle.net/10470/27762
http://hdl.handle.net/10470/2776202e99c2a-3228-49a2-b3e5-3615796a6153
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
KJ00006015112.pdf (1.3 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2010-08-10 | |||||
| タイトル | ||||||
| タイトル | 視神経脊髄炎と抗アクアポリン抗体(神経内科学教室岩田誠教授退任記念特別号) | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 別タイトル | ||||||
| その他のタイトル | Neuromyelitis Optica and Autoantibodies to Aquaporin(Special Issue in Hornor of the Retirement of Professor Makoto Iwata at the Department of Neurology, Tokyo Women's Medical University) | |||||
| 著者名 |
太田, 宏平
× 太田, 宏平 |
|||||
| 著者別名 | ||||||
| 識別子Scheme | WEKO | |||||
| 識別子 | 298874 | |||||
| 姓名 | OTA, Kohei | |||||
| 出版者 | ||||||
| 出版者 | 東京女子医科大学学会 | |||||
| 受付日付 | ||||||
| 日付 | 2010-08-10 | |||||
| 日付タイプ | Created | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0040-9022 | |||||
| NCID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AN00161368 | |||||
| 書誌情報 |
東京女子医科大学雑誌 巻 78, 号 Extra, p. E42-E52, 発行日 2008-02-25 |
|||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Neuromyelitis optica (NMO), also known as Devic's disease, is thought to be a severe inflammatory demyelinating disease of the central nervous system (CNS) that mainly involves the optic nerve and spinal cord. Because of the clinical and pathological manifestation, NMO is considered as a severe form of multiple sclerosis (MS). Here in Japan, it is not only diagnosed as optic-spinal MS, but is often treated with an immunomodulating agent, interferon beta. In 2004, NMO-IgG or an autoantibody to aquaporin-4 of perivascular astroglia and ependymal cells of the CNS, which is a first specific marker of the demyelinating disease, was identified in the serum of NMO patients, and clearly distinguished NMO from MS. Therefore, the pathogenesis and treatment of NMO might be different from that of MS. For a reference on an advanced management of a patient with NMO, recently reported data on the clinical features and possible treatments of NMO are reviewed and summarized in this article. | |||||
| 注記 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 神経内科学教室岩田誠教授退任記念特別号 | |||||
| 著者所属 | ||||||
| 値 | 東京理科大学理学部:東京女子医科大学医学部神経内科学 | |||||
| 著者キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | neuromyelitis optica | |||||
| 著者キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Devic's disease | |||||
| 著者キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | multiple sclerosis | |||||
| 著者キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | aquaporin | |||||
| 著者キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | NMO-IgG | |||||
